For the quarter ending 2025-09-30, SABS had $25,732,491 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 30,134,426 | - |
| Depreciation and amortization | 743,764 | 1,509,406 |
| Amortization of finance right-of-use assets | 21,705 | 43,412 |
| Stock-based compensation expense | 800,764 | 1,240,149 |
| Net realized and unrealized gain on equity securities | 62,829 | 1,209 |
| Change in fair value of warrant liabilities | -66,007,621 | - |
| Accretion of discounts on short-term investments | 23,681 | 28,086 |
| Accrued interest receivable | 559,954 | -54,955 |
| Prepaid expenses and other current assets | -2,131,089 | 553,279 |
| Operating lease right-of-use assets and liabilities, net | -4,124 | -59,435 |
| Accounts payable | 335,924 | 822,342 |
| Accrued expense and other current liabilities | -287,490 | 1,623,870 |
| Net cash used in operating activities | -13,050,023 | -14,948,761 |
| Proceeds from the sale of equipment | 0 | 500 |
| Purchases of investment securities | 129,868,915 | 122,924 |
| Sales and maturities of investments | 0 | 9,991,364 |
| Net cash used in investing activities | -129,868,915 | 9,868,940 |
| Proceeds from the 2025 pipe, net of series b issuance costs | 168,729,827 | - |
| Principal payments of notes payable | 3 | 275,846 |
| Principal payments on finance leases | 35,977 | 69,911 |
| Tax payments for share settlement of restricted stock units | 4,881 | 2,072 |
| Net cash provided by (used in) financing activities | 168,688,966 | -347,829 |
| Effect of exchange rate changes on cash and cash equivalents | -37,537 | 221,901 |
| Net increase (decrease) in cash and cash equivalents | 25,732,491 | -5,205,749 |
| Cash and cash equivalents at beginning of period | 8,897,966 | - |
| Cash and cash equivalents at end of period | 29,424,708 | - |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)